Reimagining (Bio)Medicalization, Pharmaceuticals and Genetics
eBook - ePub

Reimagining (Bio)Medicalization, Pharmaceuticals and Genetics

Old Critiques and New Engagements

  1. 274 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

Reimagining (Bio)Medicalization, Pharmaceuticals and Genetics

Old Critiques and New Engagements

About this book

In recent years medicalization, the process of making something medical, has gained considerable ground and a position in everyday discourse. In this multidisciplinary collection of original essays, the authors expertly consider how issues around medicalization have developed, ways in which it is changing, and the potential shapes it will take in the future. They develop a unique argument that medicalization, biomedicalization, pharmaceuticalization and geneticization are related and co-evolving processes, present throughout the globe. This is an ideal addition to anthropology, sociology and STS courses about medicine and health.

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Reimagining (Bio)Medicalization, Pharmaceuticals and Genetics by Susan Bell,Anne Figert in PDF and/or ePUB format, as well as other popular books in Social Sciences & Sociology. We have over one million books available in our catalogue for you to explore.

Information

I
Reimaginings: (Bio)Medicalization and Technoscience in the Twenty-First Century
1
Moving Sideways and Forging Ahead
Reimagining “-Izations” in the Twenty-First Century
SUSAN E. BELL AND ANNE E. FIGERT
In the Introduction to this volume, we write that medicalization is a useful concept that has been highly debated within the social sciences, history and biomedicine itself. Although we do not entirely agree with Rose who suggests “medicalization has become a clichĂ© of critical social analysis” (Rose 2007:700), his call to move “beyond medicalization” resonates with us and others. Medicalization still has utility for social analysts if we take it, following Rose (2007:702) as “the starting point of an analysis, a sign of the need for an analysis, but 
 not 
 the conclusion of an analysis”. We also do not entirely agree with Kleinman (2012) who argues that medicalization is no longer an interesting or useful concept because it applies to a process in which conditions move from one category (e.g., badness) to another (e.g., sickness). At the same time we agree with Kleinman that either/or thinking cannot grasp complex processes leading to and emanating from social suffering and global health inequality. In addition to adding related concepts (biomedicalization, pharmaceuticalization and geneticization) alongside that of medicalization, scholars are more recently using the concept of medicalization in new and different ways such as “ambivalent medicalization” (Crowley-Matoka and True 2012) and what might be called “simultaneous medicalization and demedicalization,” in which professional groups such as lactation consultants are actively working toward demedicalization and medicalization at the same time (Torres 2014).
The role of the analyst of this phenomenon is to not only critique but to engage with its messy and theoretical/practical areas. As the title of the Introduction to this book suggests (Bell and Figert 2015), we still need to engage older critiques about medicalization processes but with newer studies and new tools. To do so, we embrace the conceptual tools of biomedicalization, pharmaceuticalization, the pharmaceuticalization of public health, and geneticization in order to show that medicalization is a capacious concept but it may not fully capture the global dynamics of biomedicine, the pharmaceutical industry and technologies of genetics in medicine. There is certainly a fair amount of overlap but medicalization alone is not adequate for understanding what is going on in the globalizing world of the twenty-first century precisely because it is rooted in modernity and categorical thinking (Bell and Figert 2012a). These “-izations” are related and coevolving concepts and processes; this becomes especially visible when analyzed within a global context. In this chapter we look back over the past forty years of scholarship on medicalization, turn sideways to other disciplines that contribute to this growing field and look ahead to the next decades. We argue that alone each of the concepts captures distinct processes, that each is related to the others, and that each sometimes but not always overlaps with another. In this chapter, we suggest that instead of throwing out one or all of the “-izations” we can move sideways and forge ahead by examining new ways of thinking: globally, scientifically, socially.
Historicizing Medicalization
Our discussion begins here with the widely accepted definition and description of medicalization from US sociologist Peter Conrad as “defining a problem in medical terms, usually as an illness or disorder, or using a medical intervention to treat it” (2005:3; emphasis in original) and as “a process by which nonmedical problems become defined and treated as medical problems, usually in terms of illness and disorders” (2007:4). Historians and anthropologists document how medicalization as a phenomenon (as opposed to an analytic term) has its beginnings in late seventeenth- and early eighteenth-century Western modernization along with the application of scientific knowledge to social life (Lock 2004). This location of medicalization within large-scale social processes such as modernization and positivism and public health programs of the modern state echoes throughout the historical and anthropological literature (Nye 2003; Rosenberg 2006). To simplify, “medicalization” is a process associated with modernity, and reflects societal and medical practices designed to control and regulate diseases, illnesses and injuries. Foucault’s (1965, 1977[1975]) work on the modern state, the clinical gaze and the embodiment of surveillance and control is often cited in the medicalization literature as a major influence on the scholarship about this process (e.g., Lupton 1997; Nye 2003). According to Foucault, medicalization as a process was co-constructed along with modern capitalism and the state. The process of medicalization exemplifies a modern mechanism of power – a manifestation “of the right of the social body to ensure, maintain, or develop its life” (Foucault 1978:136). The modern state replaced the ancient right to take life with the power to foster life. The power over life evolved in two forms that were “linked together by a whole intermediary cluster of relations” (Foucault 1978:137): disciplining the individual body and optimizing its capabilities and regulating the species body (population). The beginning of what Foucault called “biopower” (Foucault 1978:140) is marked by the “explosion of numerous and diverse techniques for sub-jugation of bodies and the control of populations.” Whether medicalization was “co-constitutive of modernity” (Clarke et al. 2003:164) or “the product as well as the cause of societal faith in medical knowledge and practice” (Ballard and Elston 2005:237), the turn to medicine as an institution of social control was part of a more general process of modernization.1
The concept of medicalization has its roots in mid- to late twentieth-century scholarship in the humanities and social sciences. Many scholars trace the study of what is now called “medicalization” to the 1960s and the work of anti-psychiatrists such as Szasz (1974[1961]) and Laing (1961). Szasz, Laing and others argued that Western medical professionals had the authority and power to classify and diagnose “normal” everyday feelings and behaviors and transform them into psychiatric illnesses (usually for the economic and professional benefit of psychiatrists and psychologists). Other scholars connect it with the concerns expressed by Illich (1975) in the 1970s about medical imperialism and the ever expanding reach and influence of the institution of medicine as the foundation from which medicalization studies emerged.
The concept of medicalization was introduced into the medical sociology literature in the 1970s to understand and look critically at “the involvement of medicine in the management of society” (Zola 1972:488; see also Pitts 1968 for one of the earliest references as it related to definition and social control of deviance). Medical sociologists began to use the concept of “medicalization” to examine the dynamics of an expanding medical institution and the related processes of professional authority, control and the construction (and active defense) of medical diagnoses (Freidson 1970; Zola 1972). At this time, the connection between the dynamics of medicalization and those of deviance and social control was highlighted with examples such as hyperactivity, sexuality and alcoholism (Conrad and Schneider 1980). Scholars showed how deviance was gradually transformed from a religious and criminal problem into a medical problem that is defined, treated and controlled by the medical establishment.
A substantial portion of the early sociological work on medicalization focused specifically upon the technically competent power and authority of physicians in modern society and in the medical encounter itself. As numerous reviews of the literature point out, in medical sociology, “medicalization” has its roots in Parsons’ concept of the sick role (1951). At one level, the sick role refers to individuals and interactions in the medical social control of deviance. However, the sick role is also about the larger social structures in which the interactions are situated – the institution of medicine and physicians’ state sanctioned authority to diagnose and treat diseases in people seeking “technically competent” help (Freidson 1970). By virtue of having the authority and professional power in modern society to define and control what is formally recognized as a disorder, sickness or deviance, physicians play an important role in the medicalization process (Freidson 1970; Zola 1972; Illich 1975; Conrad and Schneider 1980).
Early sociological analyses often adopted a modernist framework to examine how the institution of medicine developed and applied a scientific worldview to elements of physical and emotional life. By this we mean a worldview in which policies and practices value and are designed to promote progress, rationalization, standardization, precision, enhanced control over external nature, and mass production and consumption (Bell and Figert 2012a:776). Accordingly, in medicalization theory the concept of “control” was prominent, used to explain consumer demand (to control and improve upon their physical bodies) as well as medical imperialism (to control deviance through surveillance and the rational application of science to everyday life), and the turn to treatment as opposed to incarceration or punishment (Lock 2004). As Irving Zola wrote, medicine was “becoming the new repository of truth, the place where absolute and often final judgments are made by supposedly morally neutral and objective experts. And these judgments are made, not in the name of virtue or legitimacy, but in the name of health 
 [it] is largely an insidious and often undramatic phenomenon accomplished by ‘medicalizing’ much of daily living, by making medicine and the labels ‘healthy’ and ‘ill’ relevant to an ever increasing part of human existence” (Zola 1972:487).
Throughout the period from the 1970s to the early 1990s medicalization scholars continued to refine the concept by documenting how the jurisdiction of medicine expanded and redefined elements of the life cycle and moral, social and legal problems and turned them into medical matters. In the 1980s, most of the sociologically generated scholarship moved away from an explicit focus on deviance and scholarship in the USA took a social constructionist approach to medicalization in its examination of the construction of diagnostic categories and professional process and social control of behaviors (Conrad 1992).
During the early part of this period, an important turn in the development of medicalization scholarship came about when researchers began to point out that medicalization was not just a process done to people but that people and groups were also active agents in advocating for or against diagnoses or the medicalization or demedicalization of life processes.2 Using perspectives from both the sociology of professions and the sociology of scientific knowledge, medical sociologists were heavily engaged in documenting cases of medicalization such as in the care of children and of veterans of the Vietnam War (Halpern 1990; Scott 1990). Feminist scholars focused on women’s bodies (e.g., Riessman 1983; Bell 1987b) and documented cases of the gendered nature of medicalization. Women’s health movements (Boston Women’s Health Book Collective 1973) also emphasized the unique ways in which women’s bodies were more susceptible to medicalization through processes such as childbirth, PMS and menopause (McCrea 1983; Riessman, 1983; Bell 1987a; Figert 1995). By the 1990s the medicalization analysis of gender moved its focus beyond the reproductive realm for women (Plechner 2000; Riska 2003; Barker 2005) and medicalization scholars began to ask how, why and under what circumstances men’s bodies are also medicalized (Loe 2004; Rosenfeld and Faircloth 2006; Conrad 2007).3
The 2000s: Putting the Bio- into Medicalization, Pharmaceuticals and Genomics
The rise of gender scholarship, the growth of the institution of medicine and the pharmaceutical industry, and other factors contributed to continued scholarly interest in developing the concept and studying the dynamics of medicalization and its related processes in the 2000s. Scholarship revitalized and refocused our analytic gaze from the power and authority of the medical profession and the documentation of cases of medicalization to consider the active participation of individual patient/consumer/users individually and collectively (Brown and Zavestoski 2004; Crossley 2006), resistance to pharmaceuticals (Figert 2011; Williams, Martin and Gabe 2011), and the use of medical prescription drugs for nonmedical purposes (Williams, Gabe and Davis 2008). It has also explored new “engines” of medicalization including the pharmaceutical industry (Conrad 2005), and the role of technoscience (Clarke et al. 2003).
Scholars from many disciplines are also questioning the adequacy of medicalization as a conceptual tool for understanding these processes. One reason is that physician power and authority is changing – indeed waning – as a result of healthcare reforms, insurance policies and (in the USA and New Zealand) direct-to-consumer advertising (DTCA) of pharmaceuticals (Lock 2004; Rose 2007). Even though the medical profession and physicians remain key players in medicalization they are no longer its major promoters (Conrad 2007:156).
Another significant change is that the pharmaceutical industry has become an important proponent of medicalization by targeting physicians through physician-directed communications and targeting (potential) patients directly and indirectly with advertisements (Abraham 2010a; Padamsee 2011). Medicalization theory assumes that the transformation from deviance as badness to deviance as sickness is associated with less stigma both to the individual and to the group of people affected. Big Pharma has held out advertising as a strategy for not only medicalizing but also destigmatizing conditions such as erectile dysfunction, social anxiety and depression. With greater awareness of certain conditions, comes the promise of normalizing and destigmatizing the effect of the conditions (Phelan 2005). As Payton and Thoits write, medicalization was “thought to reduce the blame and stigma attached to deviant conditions such as mental illness” (2011:56). The dynamics of medicalization involving mental illness both in the USA and in other countries are, however, much more complex than this argument assumes. The results of DTCA in the USA in reducing stigma have been mixed, especially regarding mental illness. Payton and Thoits investigated whether or not the rise of DTCA for depression drugs alters negative public opinion about depression and mental illness more generally and found that DTCA did not change Americans’ negative perceptions about mental illness but did promote the greater acceptance of medical interventions for mental illness (2011). Pescosolido et al. (2010) found similar results in that DTCA increased public acceptance about the biomedical causes of mental illness and increased support for biomedical treatments and services but did not increase overall acceptance of people with mental illness. Thus, DTCA garners support for medicalization and treatment of mental illness pharmaceutically but this does not mean that people with mental illness are any less stigmatized in the USA as the recent debates on gun violence and lack of mental healthcare has made clear.
The global dynamics of the medicalization of mental illness are also complicated, uneven and at times contradictory as studies of prescriptions in Chile, Japan and Argentina demonstrate. Cuthbertson documents the use of antidepressants in Chilean mental health Clinics as a form of “pharmaceutical governance” by the state (2015, Chapter 7, this volume). In Chile, even when depression is viewed as a medical illness, it is also viewed both as a threat to individual worker productivity and to the national economy. In this case then the medicalization of depression and its pharmaceutical treatment is taken to mean an entirely different thing than it might in a different country such as in the USA. In the USA depression is individualized but not seen as a threat to the national economy. As Applbaum (2006) suggests, the later introduction of newer antidepressants (selective serotonin reuptake inhibitors or SSRIs) such as Prozac in Japan in the mid- to late 1990s was the result of successful global marketing strategies by pharmaceutical companies and not by the state. In this case the harmonization of clinical research data from global clinical trials was key. Successful marketing depended on and produced organizational changes in Japanese governmental agencies about accepting foreign clinical research da...

Table of contents

  1. Cover Page
  2. Half-Title Page
  3. Title Page
  4. Copyright Page
  5. Contents
  6. Foreword
  7. Acknowledgments
  8. Introduction: Outlining Old Critiques and New Engagements
  9. Part I Reimaginings: (Bio)Medicalization and Technoscience in the Twenty-First Century
  10. Part II Pharmaceuticals
  11. Part III Genetics/Genomics
  12. Epilogue: Mapping the Biomedicalized World for Justice
  13. Contributor Biographies
  14. Index